Eli Lilly and Co (LLY) Opciones

Eli Lilly and Company $LLY Total Debt (mrq) $31.23B Massive debt compared to dwinding cash. Pump and dump

Another gloom and doomer . Lilly is fine . I worked there over 10 years and they have a ton in the pipeline . It needs a breather . Crash my a$$

RNAZ micro rna cancer cure ELAB el-22 obesity target buyout in progress

Are you saying small biotech has a chance...? I was thinking the other way...

Eli Lilly has been a major player in CNS disorders, particularly with treatments for depression (e.g., Prozac) and schizophrenia. They are actively exploring new areas in psychiatry, including the potential for psychedelics.

Lilly has shown interest in novel treatments for depression and anxiety and has partnered with companies in the psychedelic space. Their expansion into the psychedelic field could be an opportunity to leverage MindMed's expertise in developing treatments using substances like LSD and MDMA.

I am wondering if they (or others) would might possibly acquire them.

I've been waiting and waiting for this one to pull back and it has. However, it is fighting mightily to hold support here....Right now I'm thinking it looks moderately hopeful here, but I think $NVO has become the better play now.

Industry changing direction. Big Pharma going south! LLY a major short candidate going into 2025.

$1000 strikes for Jan 2025 look juicy.

$LLY

why?

Big Pharma to crash hard. Be prepared!

Wonder if Lily Buys SMMT.
$LLY

LLY offers Zepbound in_single-use_vials_at_sharply_reduced_prices—(yesterday’s news):

https://www.nytimes.com/2024/08/27/well/eli-lilly-zepbound-price.html On Tuesday, Eli Lilly announced that it would start selling low doses of its weight-loss drug Zepbound in vials… — at a far lower price than its pens, which come with pre-filled doses. These vials will be made available only through LillyDirect, a telehealth platform the company launched in January (https://investor.lilly.com/news-releases/news-release-details/lilly-launches-end-end-digital-healthcare-experience-through ).

…The vials are significantly cheaper than Zepbound pens, which cost just over $1,000 a month without insurance. A month’s supply of the 2.5-milligram dose will cost $399, and a month’s worth of the five-milligram dose will cost $549.

… The company will offer vials with only the two lowest doses of Zepbound. Many patients stay on a five milligram dose… but some gradually increase their dose, up to a maximum of 15 milligrams. Any patient interested in taking more than the five-milligram dose would have to transition to the pens.

…the move could help Lilly regain customers who are currently getting compounded tirzepatide, which typically costs between roughly $250 and $450 a month. Why would anyone want a compounded formulation of tirzepatide derived from Chinese API when they can get the real thing from LLY at close to the same price?

LLY new 52=week high

To quote Areosmith ' I'm back in the saddle again' . 💰

In the green premarket again. 🍷

Bought back in at open today. 🍷

In regards to new a pharma product.

$LLY Chart from #DDAmanda - #1 Stock Screener :



Z

Just sold my LLY shares. Wonderful way to ease into the weekend. Good luck to everyone today.

Added @ $866.29

Going to be another green day.

I don't think they have sales in Europe yet, that'll change. 💰💰💰

Uh, probably not .

LLY new 52=week high

Let's go fans 1000.00!!!

LLY new 52 week high

LLY new 52 week high

LLY 10Q due 4/30
Next day setttlement begins 5/28

FDA advises LLY it wants AdCom meeting. Portends delay. Meanwhile NVO CEO was interviewed on CNBC-TV this morning, repeats NVO’s PR warning dated in January 2024 that it will not have manufacturing capacity to fill demand for its weight loss drug until 2006(?).

Sell now boys you had a great run

LLY new 52 week high

LLY new 52 week high

Eli Lilly was investigating Talampanel prior to 2010

For the treatment of epilepsy, malignant gliomas and ALS
development codes LY-300164 , LY300164
results from the trial for ALS have been found negative
Talampanel is not currently under development.
It showed effectiveness for epilepsy in clinical trials but its development was suspended due to its poor pharmacokinetic profile, namely a short terminal half-life (3 hours) that necessitated multiple doses per day.
RespireRx Pharmaceuticals $ RSPI a little unknown company KRM–II–81 has shown promising results for Epilepsy.
Has fully suppressed the epileptiform activity in the excised brain tissue from a 19-year-old patient with pharmaco-resistant epilepsy.

I bought Lilly about a year ago based on Mounjaro and knowing it was going to be a success. I am a FAmily Doc who has done bariatric medicine for 30 years. Zepbound definitely is inducing more weight loss than Ozempic (Wegovy) but I am getting concerned over the number of patients that are stopping zepbound / Mounjaro due to side effects, seems a lot more than on Ozempic ( Wegovy) .

Incredible, isn’t it
What gets me about these social media bozos is they actually believe they will become Boca Raton rich by day trading sub $1 stocks
Because they are incapable of researching companies

800$ tomorrow?

LLY new 52=week high

LLY new 52 week high

LLY new 52 week high

LLY new 52 week high

Shorted at 625.

Great news on their new diabetes drug.

Looking for the bottom ,not yet :)

LLY new 52 week high

Amazing financials

Billionaires dream a while back, speculating

Interesting company

Wowwwwwww

Knew this company from the 80 ssssss

LLY new 52 week high

Who is pumping?